The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Belzutifan for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: HIF-2 Alpha Inhibitor

Oral hypoxia-inducible factor 2 alpha inhibitor for VHL syndrome-associated tumors including renal cell carcinoma, hemangioblastoma and pancreatic neuroendocrine tumors

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Belzutifan for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: HIF-2 Alpha Inhibitor?

Belzutifan is oral selective HIF-2 alpha inhibitor disrupting transcription of pro-angiogenic and proliferative genes including VEGF and CCND1.

VHL disease occurs in approximately 1 in 36,000 births with germline VHL gene loss-of-function mutations.

Manifestations include clear cell renal cell carcinoma, central nervous system hemangioblastomas, retinal angiomas, pancreatic neuroendocrine tumors and pheochromocytomas.

FDA approval is for VHL-associated tumors including RCC, CNS hemangioblastomas and pancreatic NETs not requiring immediate surgical intervention.

Lifetime tumor burden requires multidisciplinary surveillance and intervention with targeted therapy reducing surgical needs.

Symptoms

Anemia is most common adverse effect related to mechanism of action requiring monitoring and erythropoietin support if severe.
Hypoxia and decreased oxygen saturation reflect HIF pathway inhibition and erythropoiesis suppression.
Fatigue, headache and dizziness affect quality of life requiring symptom management.
Nausea, decreased appetite and weight changes are common gastrointestinal effects.
Embryofetal toxicity warrants effective contraception during therapy and for one week after discontinuation.

Risk Factors

Family history of VHL syndrome with germline mutation testing identifies at-risk individuals enabling early surveillance.
Age-stratified surveillance protocols include annual MRI brain and spine, retinal examination, abdominal imaging.
Pre-existing anemia, smoking or pulmonary disease increases hypoxia complication risk.
Concurrent strong CYP3A4 inhibitors require dose adjustments given metabolic interactions.
Pregnancy and lactation considerations require effective contraception throughout therapy.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Confirmed VHL disease with germline mutation and tumor manifestations warrants hereditary cancer evaluation.
  • Renal cell carcinoma not requiring immediate nephron-sparing surgery represents indication for systemic therapy.
  • CNS hemangioblastoma with progressive symptoms or growth despite surveillance warrants intervention discussion.
  • Pancreatic neuroendocrine tumors meeting size criteria with risk of malignant transformation require evaluation.
  • Multidisciplinary care including urology, neurosurgery, ophthalmology, medical oncology and genetics optimizes outcomes.

Treatment Methods

01
Belzutifan 120 mg orally once daily continuous dosing represents standard regimen.
02
Hemoglobin monitoring at baseline and regularly during therapy with dose modification for severe anemia.
03
Oxygen saturation monitoring with awareness of hypoxia symptoms and intervention as needed.
04
Comprehensive surveillance imaging continues including MRI brain and spine, abdominal imaging, retinal examination.
05
Multidisciplinary VHL disease management with coordinated specialist care including genetic counseling, family screening and supportive care optimizes long-term outcomes for this lifetime hereditary tumor predisposition syndrome.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.